Jasper Therapeutics Inc
NASDAQ:JSPR
Jasper Therapeutics Inc
Accrued Liabilities
Jasper Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
Accrued Liabilities
$7.9m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Jasper Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
7.9m
USD
Based on the financial report for Dec 31, 2023, Jasper Therapeutics Inc's Accrued Liabilities amounts to 7.9m USD.
What is Jasper Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
46%
Over the last year, the Accrued Liabilities growth was 55%. The average annual Accrued Liabilities growth rates for Jasper Therapeutics Inc have been 46% over the past three years .